Clearside Biomedical Management
Management criteria checks 3/4
Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 7.25 years. directly owns 0.49% of the company’s shares, worth $3.19K. The average tenure of the management team and the board of directors is 7.3 years and 7.8 years respectively.
Key information
George Lasezkay
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 7.3yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
CLSD.Q: Bankruptcy Sale Process Will Unlock Significant Equity Upside
Analysts have sharply raised their price target on Clearside Biomedical to approximately 90 dollars from 6 dollars, citing a reassessment of fair value despite more conservative assumptions on revenue growth, profitability, and required returns. What's in the News Clearside Biomedical filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware, listing assets of 1 to 10 million dollars and liabilities of 50 to 100 million dollars (court filing).
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Despite a significant increase in the consensus analyst price target from $4.00 to $60.00, analysts remain cautious due to Clearside's uncertain strategic direction, tough financing environment, and diminishing cash runway, which cloud visibility into the company's future. Analyst Commentary Announcement of exploring strategic alternatives created uncertainty around Clearside's future direction.
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval.Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
The analysts covering Clearside Biomedical, Inc. ( NASDAQ:CLSD ) delivered a dose of negativity to shareholders today...Clearside Biomedical Q2 2022 Earnings Preview
Clearside Biomedical (NASDAQ:CLSD) is scheduled to announce Q2 earnings results on Tuesday, August 9th, before market open. The consensus EPS Estimate is -$0.13 (-18.2% Y/Y) and the consensus Revenue Estimate is $0.3M (-61.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. Revenue estimates have seen 0 upward revisions and 1 downward.Clearside Biomedical: A Pivotal 2022 Ahead
XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3. Partner Aura Biosciences will select the route of administration for lead drug candidate AU-011. Clearside is actively seeking gene therapy partners.Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis. XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it. Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Clearside's Value Proposition Is Far From Clear
Clearside is developing treatments for diseases of the suprachoroidal space of the eye. However, even its latest stage asset has very little monetary value. Self-owned programs are in early stages and face stiff competition.We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$26m |
| Jun 30 2025 | n/a | n/a | -US$28m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$1m | US$547k | -US$34m |
| Sep 30 2024 | n/a | n/a | -US$32m |
| Jun 30 2024 | n/a | n/a | -US$33m |
| Mar 31 2024 | n/a | n/a | -US$35m |
| Dec 31 2023 | US$2m | US$547k | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$36m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$2m | US$532k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$5m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | US$83k |
| Dec 31 2021 | US$2m | US$516k | US$376k |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$1m | US$503k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$14m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$1m | US$385k | -US$31m |
Compensation vs Market: Insufficient data to establish whether George's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
CEO
George Lasezkay (74 yo)
Dr. George M. Lasezkay, Pharm D, & J.D. serves as Principal Executive Officer at Clearside BioMedical, Inc. since July 18, 2025 and had been Chief Executive Officer since March 2020 until July 18, 2025 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director & Principal Executive Officer | 7.3yrs | US$1.30m | 0.49% $ 3.2k | |
| Principal Financial Officer & Principal Accounting Officer | 14.5yrs | US$782.08k | 0.48% $ 3.1k | |
| Head of Investor Relations | no data | no data | no data | |
| Senior Vice President of Engineering & Manufacturing | 3.5yrs | no data | no data |
Experienced Management: CLSD.Q's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director & Principal Executive Officer | 8.9yrs | US$1.30m | 0.49% $ 3.2k | |
| Independent Director | 14.5yrs | US$96.05k | 0.10% $ 653.7 | |
| Independent Director | 4.3yrs | US$93.55k | 0.023% $ 149.6 | |
| Independent Director | 7.8yrs | US$98.55k | 0% $ 0 | |
| Independent Director | 14.5yrs | US$117.72k | 0.22% $ 1.5k | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 14.5yrs | US$81.05k | 0.065% $ 425.4 | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Independent Director | 6.3yrs | US$93.55k | 0.12% $ 775.0 | |
| Independent Director | 10.4yrs | US$101.05k | 0% $ 0 | |
| Chairman of Scientific Advisory Board | no data | US$749.87k | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
Experienced Board: CLSD.Q's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 09:18 |
| End of Day Share Price | 2026/07/01 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clearside Biomedical, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |
| Debanjana Chatterjee | JonesTrading Institutional Services, LLC |
| Anupam Rama | J.P. Morgan |